6tcs: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6tcs' size='340' side='right'caption='[[6tcs]], [[Resolution|resolution]] 2.30Å' scene=''> | <StructureSection load='6tcs' size='340' side='right'caption='[[6tcs]], [[Resolution|resolution]] 2.30Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6tcs]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TCS OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[6tcs]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TCS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TCS FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tcs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tcs OCA], [https://pdbe.org/6tcs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tcs RCSB], [https://www.ebi.ac.uk/pdbsum/6tcs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tcs ProSAT]</span></td></tr> | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 16: | Line 17: | ||
</div> | </div> | ||
<div class="pdbe-citations 6tcs" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6tcs" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Beavil | [[Category: Beavil AJ]] | ||
[[Category: Ceska | [[Category: Ceska T]] | ||
[[Category: Davies | [[Category: Davies AM]] | ||
[[Category: Henry | [[Category: Henry AJ]] | ||
[[Category: McDonnell | [[Category: McDonnell JM]] | ||
[[Category: Mitropoulou | [[Category: Mitropoulou AN]] | ||
[[Category: Sutton | [[Category: Sutton BJ]] | ||
Latest revision as of 15:59, 24 January 2024
Crystal structure of the omalizumab scFvCrystal structure of the omalizumab scFv
Structural highlights
Publication Abstract from PubMedImmunoglobulin E (IgE) plays a central role in the allergic response, in which cross-linking of allergen by FcepsilonRI-bound IgE triggers mast cell and basophil degranulation and the release of inflammatory mediators. The high-affinity interaction between IgE and FcepsilonRI is a long-standing target for therapeutic intervention in allergic disease. Omalizumab is a clinically approved anti-IgE monoclonal antibody that binds to free IgE, also with high affinity, preventing its interaction with FcepsilonRI. All attempts to crystallize the pre-formed complex between the omalizumab Fab and the Fc region of IgE (IgE-Fc), to understand the structural basis for its mechanism of action, surprisingly failed. Instead, the Fab alone selectively crystallized in different crystal forms, but their structures revealed intermolecular Fab/Fab interactions that were clearly strong enough to disrupt the Fab/IgE-Fc complexes. Some of these interactions were common to other Fab crystal structures. Mutations were therefore designed to disrupt two recurring packing interactions observed in the omalizumab Fab crystal structures without interfering with the ability of the omalizumab Fab to recognize IgE-Fc; this led to the successful crystallization and subsequent structure determination of the Fab/IgE-Fc complex. The mutagenesis strategy adopted to achieve this result is applicable to other intractable Fab/antigen complexes or systems in which Fabs are used as crystallization chaperones. Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.,Mitropoulou AN, Ceska T, Heads JT, Beavil AJ, Henry AJ, McDonnell JM, Sutton BJ, Davies AM Acta Crystallogr F Struct Biol Commun. 2020 Mar 1;76(Pt 3):116-129. doi:, 10.1107/S2053230X20001466. Epub 2020 Mar 2. PMID:32133997[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||